线粒体:组织癌症脱离化疗的主要器官
Samaneh Mostafavi1, Nahid Eskandari2
1Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Cancer reports (Hoboken, N.J.)
|December 28, 2023
概括
线粒体在癌细胞逃避化疗中发挥着至关重要的作用. 了解它们的生物特征,如代谢重编程,可以揭示新的癌症药物设计的漏洞.
科学领域:
- 线粒体生物学 线粒体生物学
- 癌细胞的代谢 癌细胞的代谢
- 化学电阻机制 化学电阻机制
背景情况:
- 化学抵抗在癌症治疗中是一个重大挑战.
- 线粒体是瘤生长和生存的组成部分.
- 线粒体功能有助于癌细胞逃脱各种疗法.
研究的目的:
- 确定能够使癌细胞逃避治疗的关键线粒体特征.
- 探索线粒体作为新型抗癌药物设计的潜在目标.
主要方法:
- 关于癌症中线粒体生物学现有文献的综述.
- 分析线粒体在瘤增殖和抗药性中的作用.
- 研究特定的线粒体特征,有助于治疗逃避.
主要成果:
- 线粒体对于瘤生长至关重要,并且在癌症进展中具有动态作用.
- 线粒体代谢物影响细胞信号通路,这对增殖和耐药性至关重要.
- 癌细胞利用线粒体特征来适应治疗引起的压力.
结论:
- 线粒体的生物特征,包括氧化还原平衡,DNA枯竭和代谢重编程,赋予癌细胞灵活性.
- 这些适应能力使得癌细胞能够在治疗干预的情况下生存和增殖.
- 针对这些线粒体的脆弱性可能是克服抗化学性能的有希望的策略.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Electron Transport Chain: Complex I and II
13.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitochondria
12.8K
Mitochondria are eukaryotic cellular organelles that are known to produce energy through a process called oxidative phosphorylation. Besides their primary function, mitochondria are involved in various cellular processes, including cell growth, differentiation, signaling, metabolism, and senescence. Age-related changes cause a decline in mitochondrial quality and integrity due to increased mitochondrial mutations and oxidative damage. Thus, aging can severely impact mitochondrial functions,...
12.8K
Metastasis
5.6K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


